// App-Quantinova.ai

3747 : Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Researchers

Presenter

  • Jorge E. Cortes

Principal Investigators

  • Moshe Talpaz

  • John F. DiPersio

  • Daniel J DeAngelo

  • Elisabetta Abruzzese

  • Delphine Rea

  • Michele Baccarani

  • Martin C Muller

  • Carlo Gambacorti-Passerini

  • Stephane Wong

  • Dong-Wook Kim

  • David J. Dorer

  • Ronald Keith Knickerbocker

  • Victor M. Rivera

  • Tim Clackson

  • Christopher D. Turner

  • Frank G Haluska

  • Francois Guilhot

  • Michael W. Deininger

  • Andreas Hochhaus

  • Timothy Hughes

  • Javier Pinilla-Ibarz

  • John M Goldman

  • Maritza Lienlaf

  • Philipp le Coutre

  • Ronald Paquette

  • Charles Chuah

  • Franck E. Nicolini

  • Jane Apperley

Medical Centers

  • Urologische Klinik Universitatsmedizin Mannheim, Mannheim, Germany

  • Ematologia, Ospedale S. Eugenio, Universita Tor Vergata, Rome, Italy

  • Tampa, FL, USA,

  • Institute of Pathology, Charite Universitatsmedizin Berlin, Berlin, Germany

  • Imperial College, Department of Haematology, Hammersmith Hospital, London, United Kingdom

  • Haematology Directorate, SA Pathology, Adelaide, Australia

  • Department of Obstetrics and Gynecology, Universitatsklinikum Halle, Halle, Germany

  • Centre Hospitalier Lyon-Sud, Pierre-Benite, France

  • Service des Maladies du Sang, Hopital Saint-Louis, Paris, France

  • Unita di Ricerca Clinica - Ematologia, Azienda Ospedaliera San Gerardo/University of Milano Bicocca, Monza, Italy

  • Department of Histopathology, Imperial College London, London, United Kingdom

  • Department of Hematology, Singapore General Hospital, Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore

  • CHU Poitiers, Poitiers, France

Locations

  • Italy

  • Singapore

  • Germany

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • ARIAD Pharmaceutical

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Dyslipidemia

  • Thrombocytopenia

  • Pancreatitis

  • Neutropenia

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

  • Breakpoint Cluster Region

  • Creatinine

Drug/Treatment

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

  • lipase

Outcome

  • N/A

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved